| Literature DB >> 32055487 |
Harsha R Mittakanti1, James R Porter1.
Abstract
Retroperitoneal lymph node dissection (RPLND) can been employed as primary treatment for stage I non-seminomatous germ cell tumor (NSGCT) as well as for treatment of post-chemotherapy masses. Open RPLND (O-RPLND) has long been the standard approach for lymphadenectomy, but is associated with significant morbidity. Laparoscopic RPLND (L-RPLND) was developed to mitigate the morbidity associated with O-RPLND, but is a technically challenging procedure requiring significant experience with laparoscopic dissection and suturing to remove lymph nodes behind the great vessels and to control vascular injury. Robotic RPLND (R-RPLND) has gained traction in recent years as an alternative to both O-RPLND and L-RPLND. With superior instrument dexterity and better visualization compared to L-RPLND, and with decreased morbidity, compared to O-RPLND, R-RPLND can be performed safely and effectively. With the latest advances in robotic technology, one can perform a full bilateral dissection without needing to reposition the patient or redock the robot. R-RPLND has been applied for both primary treatment as well as in patients with post-chemotherapy residual abdominal masses. 2020 Translational Andrology and Urology. All rights reserved.Entities:
Keywords: Non-seminomatous germ cell tumor (NSGCT); lymphadenectomy retroperitoneal lymph node dissection (lymphadenectomy RPLND); robotic surgery; testis cancer
Year: 2020 PMID: 32055487 PMCID: PMC6995851 DOI: 10.21037/tau.2019.12.36
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683